Proteostasis On Track to Develop Organoids for Personalized Medicine Strategy for CF Patients with Rare Mutations
A project aimed at personalized medicine based on the use of organoids, or “mini-organs,” from cystic fibrosis (CF) patients with rare mutations is on track to collect samples from 500 people with CF by the end of April, Proteostasis Therapeutics announced. The organoids will be used as a…